Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
Standard
Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. / Carreras, E; Cahn, J Y; Puozzo, C; Kröger, Nicolaus; Sanz, G; Buzyn, A; Bacigalupo, A; Vernant, J P.
In: ANTICANCER RES, Vol. 30, No. 7, 7, 2010, p. 2977-2984.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
AU - Carreras, E
AU - Cahn, J Y
AU - Puozzo, C
AU - Kröger, Nicolaus
AU - Sanz, G
AU - Buzyn, A
AU - Bacigalupo, A
AU - Vernant, J P
PY - 2010
Y1 - 2010
N2 - This study investigated the effect of seizure prophylaxis on busulfan (Bu) plasma exposure. Twenty-four adult patients received an intravenous Bu-cyclophoshamide conditioning regimen prior to bone marrow transplantation. Busilvex (0.8 mg/kg) was administered every six hours during four consecutive days. Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion) was administered at least 12 hours prior to i.v. Bu dosing and continued until 24 hours after the last dose. Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis. Through population PK analysis, a 10% average increase (coefficient of variation, RSE=5.35%) in total clearance of Bu was quantified when Bu was associated with clonazepam as compared to phenytoin, which was considered as not being clinically relevant. The suspected induction on Bu metabolism by phenytoin should have resulted in the opposite effect. The patient efficacy and safety profiles were comparable between the two cohorts.
AB - This study investigated the effect of seizure prophylaxis on busulfan (Bu) plasma exposure. Twenty-four adult patients received an intravenous Bu-cyclophoshamide conditioning regimen prior to bone marrow transplantation. Busilvex (0.8 mg/kg) was administered every six hours during four consecutive days. Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion) was administered at least 12 hours prior to i.v. Bu dosing and continued until 24 hours after the last dose. Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis. Through population PK analysis, a 10% average increase (coefficient of variation, RSE=5.35%) in total clearance of Bu was quantified when Bu was associated with clonazepam as compared to phenytoin, which was considered as not being clinically relevant. The suspected induction on Bu metabolism by phenytoin should have resulted in the opposite effect. The patient efficacy and safety profiles were comparable between the two cohorts.
M3 - SCORING: Zeitschriftenaufsatz
VL - 30
SP - 2977
EP - 2984
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 7
M1 - 7
ER -
